Identification of Anti-Influenza A Compounds Inhibiting the Viral Non-Structural Protein 1 (NS1) Using a Type I Interferon-Driven Screening Strategy.
NS1
diverse compound library
influenza A viruses
luciferase reporter assay
pharmacophore modeling
small molecule screening
type I IFN
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
22 Jun 2023
22 Jun 2023
Historique:
received:
15
05
2023
revised:
18
06
2023
accepted:
19
06
2023
medline:
17
7
2023
pubmed:
14
7
2023
entrez:
14
7
2023
Statut:
epublish
Résumé
There is an urgent need to identify efficient antiviral compounds to combat existing and emerging RNA virus infections, particularly those related to seasonal and pandemic influenza outbreaks. While inhibitors of the influenza viral integral membrane proton channel protein (M2), neuraminidase (NA), and cap-dependent endonuclease are available, circulating influenza viruses acquire resistance over time. Thus, the need for the development of additional anti-influenza drugs with novel mechanisms of action exists. In the present study, a cell-based screening assay and a small molecule library were used to screen for activities that antagonized influenza A non-structural protein 1 (NS1), a highly conserved, multifunctional accessory protein that inhibits the type I interferon response against influenza. Two potential anti-influenza agents, compounds
Identifiants
pubmed: 37445672
pii: ijms241310495
doi: 10.3390/ijms241310495
pmc: PMC10341698
pii:
doi:
Substances chimiques
Interferon Type I
0
Viral Nonstructural Proteins
0
Antiviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Italian Ministry of Health- Istituto Superiore di Sanita' 2010
ID : Studio e sviluppo di nuovi farmaci antivirali contro infezioni da virus influenzale A-H1N1
Organisme : Istituto Superiore di Sanità
ID : Discovery of influenza A virus non-structural protein 1 (NS1) inhibitors
Organisme : NextGenerationEU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases
ID : PE00000007, INF-ACT
Références
Lancet. 2022 Aug 27;400(10353):693-706
pubmed: 36030813
Biochemistry. 2004 Feb 24;43(7):1950-62
pubmed: 14967035
J Virol. 2007 Jul;81(13):7011-21
pubmed: 17442719
Sci Rep. 2017 Mar 03;7:42717
pubmed: 28256516
J Virol. 2007 Nov;81(21):11817-27
pubmed: 17715226
Virology. 2006 Mar 30;347(1):52-64
pubmed: 16378631
Nat Microbiol. 2020 Jan;5(1):27-33
pubmed: 31768027
Am J Respir Cell Mol Biol. 2007 Mar;36(3):263-9
pubmed: 17053203
PLoS Pathog. 2012;8(11):e1003059
pubmed: 23209422
J Gen Virol. 2011 Jan;92(Pt 1):60-70
pubmed: 20881091
Cell Microbiol. 2007 Apr;9(4):930-8
pubmed: 17140406
J Virol. 2000 Sep;74(17):7989-96
pubmed: 10933707
Mol Cell. 1998 Jun;1(7):991-1000
pubmed: 9651582
N Engl J Med. 2013 May 16;368(20):1888-97
pubmed: 23577628
PLoS Med. 2013 Nov;10(11):e1001558
pubmed: 24302890
N Engl J Med. 2009 Jul 16;361(3):225-9
pubmed: 19564629
Cell. 2009 Feb 6;136(3):402-10
pubmed: 19203576
Cell Host Microbe. 2009 May 8;5(5):420-1
pubmed: 19454344
Curr Opin Virol. 2014 Oct;8:22-9
pubmed: 24866471
Virology. 2007 Jun 20;363(1):236-43
pubmed: 17320139
Antiviral Res. 2013 Sep;99(3):409-16
pubmed: 23796981
J Clin Invest. 2011 Jan;121(1):6-13
pubmed: 21206092
Antiviral Res. 2017 Jun;142:178-184
pubmed: 28377100
Nat Biotechnol. 2005 Apr;23(4):457-62
pubmed: 15778705
Antioxid Redox Signal. 2011 Aug 1;15(3):593-606
pubmed: 21366409
J Biol Chem. 2018 Sep 21;293(38):14659-14668
pubmed: 30076219
Lancet. 1998 Feb 14;351(9101):472-7
pubmed: 9482438
J Gen Virol. 2008 Oct;89(Pt 10):2359-2376
pubmed: 18796704
Cell Microbiol. 2015 Jan;17(1):131-45
pubmed: 25154738
Drug Discov Today. 2006 Dec;11(23-24):1046-53
pubmed: 17129822
Virology. 2023 Jun;583:1-13
pubmed: 37060797
Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13093-8
pubmed: 18725644
J Virol. 1994 Apr;68(4):2425-32
pubmed: 7908060
EMBO J. 1999 Apr 15;18(8):2273-83
pubmed: 10205180
Appl Microbiol. 1968 Apr;16(4):588-94
pubmed: 5647517
Bioorg Med Chem. 2012 Jan 1;20(1):487-97
pubmed: 22099257
J Virol. 2000 Dec;74(24):11566-73
pubmed: 11090154
J Comput Aided Mol Des. 2006 Oct-Nov;20(10-11):647-71
pubmed: 17124629
FASEB J. 2021 Feb;35(2):e21358
pubmed: 33538061
Cell Host Microbe. 2009 May 8;5(5):439-49
pubmed: 19454348
Pharmaceuticals (Basel). 2022 May 23;15(5):
pubmed: 35631472
J Virol. 2010 Jul;84(14):6909-22
pubmed: 20444891
J Virol. 2009 Feb;83(4):1881-91
pubmed: 19052087
Proc Natl Acad Sci U S A. 2006 May 2;103(18):7100-5
pubmed: 16627618
Virology. 2016 Jan 15;488:249-58
pubmed: 26655243
Proc Natl Acad Sci U S A. 2018 Nov 6;115(45):11613-11618
pubmed: 30352857
Virology. 2010 Dec 20;408(2):146-58
pubmed: 20934196
J Gen Virol. 1992 Dec;73 ( Pt 12):3325-9
pubmed: 1469370
Nat Med. 2005 Mar;11(3):263-70
pubmed: 15723075
EMBO J. 1994 Feb 1;13(3):704-12
pubmed: 8313914
Proc Natl Acad Sci U S A. 2007 Feb 6;104(6):1853-8
pubmed: 17267598
J Gen Virol. 1992 Jan;73 ( Pt 1):17-25
pubmed: 1530962
Eur J Med Chem. 2019 Nov 15;182:111624
pubmed: 31445234
RNA. 1995 Nov;1(9):948-56
pubmed: 8548659
Mol Cell Biol. 2014 Mar;34(6):1054-65
pubmed: 24396068
Virology. 1995 Oct 1;212(2):422-8
pubmed: 7571411
Nat Protoc. 2008;3(7):1125-31
pubmed: 18600217
PLoS Pathog. 2021 Jun 1;17(6):e1008937
pubmed: 34061908
PLoS One. 2012;7(3):e33732
pubmed: 22470468
Curr Opin Chem Biol. 2008 Jun;12(3):340-51
pubmed: 18328272
EFSA J. 2022 Oct 11;20(10):e07597
pubmed: 36247870
J Virol. 2002 Nov;76(21):11166-71
pubmed: 12368362
Biochem Biophys Res Commun. 2009 Aug 28;386(3):443-8
pubmed: 19523922
Virology. 1973 Nov;56(1):334-48
pubmed: 4795673